Table 5 Comparison of hepatitis A vaccination studies conducted in kidney transplant recipients.

From: A randomized controlled trial of comparative effectiveness between the 2 dose and 3 dose regimens of hepatitis a vaccine in kidney transplant recipients

Author

Participant, n

Age (years)

Time post-transplant (months)

eGFR (mL/min/1.73 m2)

Albumin (g/dL)

Immunosuppression

Seroconversion rate

Stark et al.

N = 39

42.5 ± 11.4

Median 96 (IQR 78–139)

NA

NA

41% CsA/AZA/Pred

27% AZA/Pred

15% CsA/Pred

71.8%

Jeon et al.

N = 52

34.1 (range, 20–56)

Mean 60.78

59.39

4.4

76.9% Tac/MPA

23.1% CsA/MPA

26.9%

The present study

N = 93 (2-dose, n = 60 and 3-dose, n = 33)

38.1 ± 10.0

Mean 72.7 ± 51.98

64.82 ± 21.9

4.2 ± 0.32

60.2% Tac/MPA

15.1% mTORi/Tac minimization

12.9% CsA-based

11.8% CNI withdrawal

50.5% (2-dose, 51.7% and 3-dose, 48.5%)

  1. IQR, interquartile range; CsA, cyclosporine A; AZA, azathioprine; Pred, prednisolone; eGFR, estimated glomerular filtration rate; Tac, tacrolimus; mTORi, mammalian target of rapamycin inhibitor; MPA, mycophenolic acid; CNI, calcineurin inhibitor.
Back to article page